Wednesday, June 10, 2026

Patent intelligence · WO

WO 2025041076

COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK

granted A61K 31/ 4155 A IA61P 35/ 00 A IA61P/3500
Status granted
Pipeline programs 6
Years to expiry 19
Applicant portfolio 25
Patent details — WO 2025041076
Jurisdiction
WO
Status
granted
Grant date
Feb 27, 2025
Expiration
Feb 22, 2045
CPC classes
A61K 31/ 4155 A I, A61P 35/ 00 A I, A61P/3500
View on Google Patents ↗

Quick answer

WO 2025041076 (COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Feb 27, 2025. Expires Feb 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 4155 A I, A61P 35/ 00 A I, A61P/3500

More from BEIGENE SWITZERLAND GMBH [CH]

Related pharmaceutical patents in our USPTO index.

  1. WO 2025252204

    DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF

    BEIGENE SUZHOU CO LTD [CN] · Expires Dec 6, 2045

    granted
  2. AU 2025242171

    A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    BEIGENE SWITZERLAND GMBH [CH] · Expires Dec 6, 2045

    granted
  3. WO 2025232885

    PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON

    BEIGENE SUZHOU CO LTD [CN] · Expires Nov 8, 2045

    granted
  4. WO 2025218772

    FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS

    BEIGENE SUZHOU CO LTD [CN] · Expires Oct 18, 2045

    granted
  5. WO 2025214466

    CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS

    BEIGENE GUANGZHOU BIOLOGICS MFG CO LTD [CN] · Expires Oct 11, 2045

    granted
  6. WO 2025201453

    COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS

    BEIGENE SUZHOU CO LTD [CN] · Expires Sep 27, 2045

    granted
  7. US 2025304535

    KAT6 Inhibitors

    BEIGENE SWITZERLAND GMBH [CH] · Expires Sep 27, 2045

    granted
  8. US 2025290040

    GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE

    BEIGENE SWITZERLAND GMBH [CH] · Expires Sep 13, 2045

    granted

Frequently asked questions

What is US patent 2025041076?

WO 2025041076 (COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK) is held by BEIGENE SWITZERLAND GMBH [CH]. Status: granted. Granted Feb 27, 2025. Expires Feb 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2025041076?

BEIGENE SWITZERLAND GMBH [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2025041076 expire?

Our index shows an expiration date of Feb 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.